Answers are grounded in this paper and cite their sources.
Despite some narrowing of the gap, ICD and CRT-D utilization remains nearly three times higher in the United States compared to Europe as of 2010.
Following the recent publication of our article1 concerning the European paradox with regard to implantable cardioverter defibrillator (ICD) device utilization in Europe (markedly lower device utilization in Europe compared with the USA), which updated several previous reports,2,3 many readers have asked for an updated version of Figure 1. We have therefore updated the figure to include data through to 2010, covering both ICD and cardiac resynchronization therapy defibrillators. The non-US data were provided by EUCOMED (updated report of November 2010). Implants per million of the population per year of ICDs and CRT-Ds in Europe and the United States. From this figure, it is apparent that the ratio of annual implants per million population in America and Europe remains surprisingly high today (675/252=2.7), although it has improved a little compared with 1995 (63/14=4.5) or 2000 (180/38=4.7). The rapid increase in device use in the USA between 2003 and 2005 is probably explained by the encouraging results of primary prevention ICD/CRT-D trial results;4,5 and the subsequent temporary fall (2005) likely reflects concerns relating to device/lead recalls.6,7 Conflict of interest: J.C. is a consultant and speaker on behalf of Boston Scientific Corporation, Medtronic, St. Jude and Biotronik.
No takes yet. Share an insight, caveat, or question.
Camm et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: